PaulaRaffinPohlmannMD

Breast Cancer, Hematologic Oncology

Associate Professor and Chief of Clinical Research, Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center

Dr. Pohlmann is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Fax+1 713-794-4385

Vanderbilt University Medical CenterResidency, Internal Medicine, 2009 - 2011
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Federal University of Rio Grande do Sul School of MedicineClass of 1992

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2013

PubMed

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, Do-Youn Oh, Andree Rorive
Nature Medicine. 2025-03-01
2 citations
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.
Kim A Reiss, Mathew G Angelos, E Claire Dees, Yuan Yuan, Naoto T Ueno
Nature Medicine. 2025-02-07
Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
Mohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, Timothy A Yap, Jordi Rodon
Clinical Cancer Research. 2025-01-22

A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-Mutated MBCJanuary 29th, 2025
MD Anderson Research Highlights for January 22, 2025January 22nd, 2025
MD Anderson Unveils January 2025 Research Breakthroughs in Cancer ScienceJanuary 22nd, 2025
Join now to see all